In vivo testing in porcine model demonstrates abluminal coating is absorbed after 6 to 9 months – Data on file at Biosensors International

1. LEADERS is a Biosensors International study. www.clinicaltrial.gov – NCT00389220

2. P. W. Serruys, LEADERS: 5-year follow-up from a prospective, randomized trial of Biolimus A9-eluting stents with a biodegradable polymer vs. sirolimus-eluting stents with a durable polymer, oral abstract presentation, TCT 2012

3. Data on file at Biosensors International

BioMatrix NeoFlex™ drug eluting stent system is CE approved. Biosensors International Group, Ltd. licenses its proprietary BA9™ drug and PLA technology to Terumo Corporation (Nobori®).

BioMatrix NeoFlex™ stent is indicated in diabetics, STEMI and ACS patients for stent lengths up to 28 mm.

CAUTION: These devices to be used by or on the order of a physician. Indications, contraindications, warnings and instructions for use can be found in the product labeling supplied with each device.

BioMatrix NeoFlex, BioMatrix Flex, Juno, Quadrature Link, Stabilum KS and SAI are trademarks or registered trademarks of Biosensors International Group, Ltd.

All cited trademarks are the property of their respective owners. Not available for sale in the United States and certain other countries. © 2014 Biosensors International Group, Ltd. All rights reserved

www.biosensors.com

Ordering Information

<table>
<thead>
<tr>
<th>Stent Length (mm)</th>
<th>8</th>
<th>11</th>
<th>14</th>
<th>18</th>
<th>24</th>
<th>28</th>
<th>33</th>
<th>36</th>
</tr>
</thead>
<tbody>
<tr>
<td>2.00</td>
<td>BMXP-2008</td>
<td>BMXP-2011</td>
<td>BMXP-2014</td>
<td>BMXP-2018</td>
<td>BMXP-2024</td>
<td>BMXP-2028</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>2.50</td>
<td>BMXP-2508</td>
<td>BMXP-2511</td>
<td>BMXP-2514</td>
<td>BMXP-2518</td>
<td>BMXP-2524</td>
<td>BMXP-2528</td>
<td>BMXP-2533</td>
<td>BMXP-2536</td>
</tr>
<tr>
<td>2.75</td>
<td>BMXP-2708</td>
<td>BMXP-2711</td>
<td>BMXP-2714</td>
<td>BMXP-2718</td>
<td>BMXP-2724</td>
<td>BMXP-2728</td>
<td>BMXP-2733</td>
<td>BMXP-2736</td>
</tr>
<tr>
<td>3.00</td>
<td>BMXP-3008</td>
<td>BMXP-3011</td>
<td>BMXP-3014</td>
<td>BMXP-3018</td>
<td>BMXP-3024</td>
<td>BMXP-3028</td>
<td>BMXP-3033</td>
<td>BMXP-3036</td>
</tr>
<tr>
<td>3.50</td>
<td>BMXP-3508</td>
<td>BMXP-3511</td>
<td>BMXP-3514</td>
<td>BMXP-3518</td>
<td>BMXP-3524</td>
<td>BMXP-3528</td>
<td>BMXP-3533</td>
<td>BMXP-3536</td>
</tr>
<tr>
<td>4.00</td>
<td>BMXP-4008</td>
<td>BMXP-4011</td>
<td>BMXP-4014</td>
<td>BMXP-4018</td>
<td>BMXP-4024</td>
<td>BMXP-4028</td>
<td>NA</td>
<td>NA</td>
</tr>
</tbody>
</table>

* In vivo testing in porcine model demonstrates abluminal coating is absorbed after 6 to 9 months – Data on file at Biosensors International

1. LEADERS is a Biosensors International study. www.clinicaltrial.gov – NCT00389220

2. P. W. Serruys, LEADERS: 5-year follow-up from a prospective, randomized trial of Biolimus A9-eluting stents with a biodegradable polymer vs. sirolimus-eluting stents with a durable polymer, oral abstract presentation, TCT 2012

3. Data on file at Biosensors International
Biosensors brings you the newest member of the BioMatrix™ family: BioMatrix NeoFlex.

With the LEADERS 1 trial 5-year results BioMatrix Flex™ achieved Gold Standard status in biodegradable technology.

Now BioMatrix NeoFlex with an enhanced stent delivery system, brings exceptional performance in complex lesions and challenging anatomy.

BioMatrix NeoFlex: one step beyond

When it comes to biodegradable polymer technology, Biosensors has developed the highest level of expertise and delivered the best results in terms of safety and efficacy, as demonstrated by the landmark LEADERS 2 trial. The additional improvement with NeoFlex is provided by an even better delivery system.

Proven efficacy of the Biolimus A9 drug

BA9 differs from common limus drugs by having increased lipophilicity properties. BA9 lipophilicity offers improved characteristics for a drug intended for local action on vascular SMC, including rapid transfer to cells in the vessel wall coupled with limited systemic exposure.